Compare Sana Biotechnology Inc (SANA) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs S&P500 ETF — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while S&P500 ETF trades at $772.52. The key difference: S&P500 ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | SPY | |
|---|---|---|
Market Cap | $1.13B | — |
Sector | Health | — |
52-Week High | $5.92 | $773.22 |
52-Week Low | $2.68 | $631.99 |
Enterprise Value | $1.05B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
SPY, the SPDR S&P 500 ETF Trust, trades at $772.47, down 0.08% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF's valuation metrics are not applicable as it tracks the S&P 500 index, and it announced a $1.90 dividend payable in July 2026. Recent news highlights the S&P 500 reaching record highs amid mixed sentiment, with some analysts cautioning on high valuations while others project further gains.
The outlook for SPY is cautiously optimistic, driven by strong market momentum and corporate earnings, but faces risks from elevated valuations and potential inflation pressures. Investment opportunity lies in broad U.S. equity exposure, while key risks include market volatility and economic data surprises.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
